A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin versus Surgery Alone in Patients with Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0), and IIIb (T3N2) Gastric Adenocarcinoma
Oxaliplatin /Capecitabine
Gastric cancer/Stomach neoplasms
Phase 3
This trial is a collaboration of Sanofi & Roche and is listed under both companies.
August 2016